Acomplia

Acomplia (known as Zimulti in the U.S.A.) is a relatively new therapeutic drug used to combat obesity in both men and women. It selectively blocks Cannabinoid-1 (CB-1) receptors in the brain, affecting metabolism. Acomplia’s active ingredient is rimonabont. Diet and exercise are the primary keys for weight loss, but Acomplia can aid the process by acting as an appetite suppressant. The drug is helpful to people who suffer from Type 2 Diabetes and/or abnormally high fat in the blood itself. Acomplia is taken in 20 mg tablet form and is available without a prescription; it is recommended that you only take one tablet per day. In test groups, Acomplia users reduced their total body weight by as much as 10 percent in two years. However, as with most diet pills, your appetite will most likely return when you stop taking the tablets. The drug is recommended for those with large waist circumference: 102 cm in men and 88 cm in women. Possible side effects are nausea and vomiting. Acomplia may also increase depressive moods in some users; if you have previously had a depressive disorder or considered suicide, do not take Acomplia. Test studies have suggested that Acomplia may help prevent cardiovascular risk. It may also reduce nicotine cravings but the results are not concrete; as of now Acomplia is not recommended for smokers who are trying to quit. Talk with your doctor before starting any drug regimen. According to some researches Acomplia is supposed to help to improve your short-term memory. A chemical called tetrahydrocannabinol is known to adversely affect your memory storage. There is evidence that Acomplia blocks the effect of this member of the cannabinoid family and allows the rats to improve their memory recall. Trials are underway to find out whether the same effect is replicated in humans.